[1]
M. Wełnicki, “Why we choose fenofibrate? Fenofibrate in long-term therapy – larger packages, greater benefits for patients with atherogenic dyslipidemia”, J EBM, vol. 18, no. 2(67), pp. 290-292, Jun. 2025.